Trial Profile
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms OPARATIC
- 05 Jun 2018 Results from OPARATIC, PARADIGM and PARADIGM-2 studies, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2018 Status changed to completed.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology